Connect blames ‘challenging funding environment’ for pausing lead global program
In a sign that the tough climate for biotechs will last into 2023, Connect Biopharma cited the icy funding environment for its decision to halt a global phase 3 program for its lead dermatitis asset while it seeks out a suitable partner.